Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients

BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC). Novel predictive markers are required to further improve the selection of patients for this treatment. We assessed the influenc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mekenkamp, Leonie JM, Tol, Jolien, Dijkstra, Jeroen R, de Krijger, Inge, Vink-Börger, M Elisa, van Vliet, Shannon, Teerenstra, Steven, Kamping, Eveline, Verwiel, Eugène, Koopman, Miriam, Meijer, Gerrit A, van Krieken, J Han JM, Kuiper, Roland, Punt, Cornelis JA, Nagtegaal, Iris D
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3508829/
https://ncbi.nlm.nih.gov/pubmed/22804917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-292
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados